Nasdaq Falls 100 Points as Inflation Data Clouds Rate Cut Hopes; Lululemon Drops 11% on Weak 2025 Outlook; AppLovin Rebounds 9.5% After Short-Seller Report.
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
This week, StockNews.AI identified and published 155 successful event alerts across multiple sectors, with almost 20% alerts showcasing price movements exceeding an impressive 10%!
*Data Captured Between 3/24 00:00am - 3/28 11:00 am EDT.
*Penny stocks are excluded from the 10%+ price change analysis.
Top 3 AI Events you can’t miss for today, 3/28.
Benzinga
BearishShortTermS&P 500Economic
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected
- U.S. stocks including S&P 500 traded lower this morning.
- PCE price index increased by 2.5% year-over-year.
- Personal income growth accelerated to 0.8%, exceeding expectations.
- Consumer discretionary shares fell by 1.4%, indicating sector weakness.
- Inflation data complicates expectations for interest rate cuts.
Investopedia
BearishShortTermLULUEarnings
Lululemon Stock Tumbles as Weak Outlook Overshadows Solid Q4
- Lululemon's Q4 performance exceeded expectations but outlook disappointed.
- First-quarter EPS guidance undercuts analyst forecasts, signaling challenges ahead.
- Share value dropped 11% after soft projections for 2025 reported.
- Analysts cut price targets, reflecting concerns over growth capability.
- Consumer caution due to inflation impacts store traffic negatively.
Barrons
BearishShortTermAPPIndustry News
AppLovin Stock Bounces Back After Plunging 20% Following Short-Seller Report - Barron's
- AppLovin stock fell 20% following a negative short-seller report.
- Shares rebounded 9.5% in premarket trading after the plunge.
- Muddy Waters Research accused AppLovin of unethical practices regarding user data.
- CEO defended the company, urging investors to analyze deeper than short reports.
- Analyst maintained a Buy rating with a $525 price target, suggesting a 101% upside.
Here’re the top 5 most-surged stocks captured by our AI Event signal this week.
*Penny stocks are not included in the list.
GlobeNewsWire
BullishLongTerm 47.97%LXEOEarnings
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
- Further FDA alignment on LX2006 regulatory pathway for Friedreich ataxia treatment.
- LX2020 trial shows significant PKP2 protein expression increases and cardiovascular improvements.
- Enrollment for cohort 2 of LX2020 is completed, data update expected in 2025.
- Cash reserves of $128.5 million projected to sustain operations until 2027.
- No serious adverse events reported, indicating a favorable drug safety profile.
GlobeNewsWire
BullishLongTerm 47.49%QNTMEarnings
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
- QNTM reported improved financial results for Q4 and FY 2024.
- Cash on hand increased to $12.1 million, ensuring operational stability.
- unbuzzd showed significant efficacy in alcohol metabolism, boosting market potential.
- Celly seeking IPO to fund growth, indicating robust investor interest.
- Lucid-MS's safety profile strengthens prospects for FDA approval.
GlobeNewsWire
VerybullishLongTerm 37.61%SLNOFDA Approval
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
- FDA approves VYKAT XR for treating hyperphagia in Prader-Willi syndrome.
- VYKAT XR is set to launch in the U.S. in April 2025.
- Approval represents a major milestone for Soleno and PWS patients.
- VYKAT XR was based on a successful Phase 3 clinical trial.
- Soleno launched a patient support program for VYKAT XR access.
PRNewsWire
BullishLongTerm 31.56%WOOFEarnings
Petco Health + Wellness Company, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
- Petco's Q4 revenue fell 7.3%, but comparable sales rose 0.5%.
- Gross profit decreased 2.8%, with adjusted EBITDA at $96.1 million.
- Net loss for 2024 sharply decreased, showing improvement over previous year.
- Guidance for FY2025 projects slight decline in revenue with improved EBITDA.
- Leadership expresses confidence in achieving double-digit EBITDA growth by 2025.
GlobeNewsWire
BullishLongTerm 29.13%LUNREarnings
Intuitive Machines Reports Fourth Quarter and Full-Year 2024 Financial Results
- Intuitive Machines reported record revenue of $228 million for 2024.
- Company's backlog increased to $328.3 million, up 22% year-over-year.
- Achieved positive gross margin for Q4 and plans for profitability in 2025.
- Raised $125 million through stock offering, strengthening financial position.
- Focus on technology expansion and leveraging government contracts for growth.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply